Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816640 | 1.00 | LMNA (0.57) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL5175242 | 0.90 | HPGD (0.53) | LMNAKMT2AHPGDMEN1POLB | |
| SCHEMBL3977492 | 0.82 | LMNA (0.65) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL3977496 | 0.82 | LMNA (0.65) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL3816853 | 0.82 | LMNA (0.62) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL4908153 | 0.82 | LMNA (0.62) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL3816761 | 0.77 | LMNA (0.67) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL3982082 | 0.76 | LMNA (0.57) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL3982077 | 0.76 | LMNA (0.57) | LMNAKMT2AHPGDMEN1MAPT | |
| SCHEMBL4968731 | 0.76 | KDM4E (0.55) | LMNAKMT2AHPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756135-B1 | ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-08-12 | — | — | EP | disclosed |
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB (HR) | 2008-10-16 | — | — | US | disclosed |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O. (HR) | 2008-10-09 | — | — | US | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255060-A1 | Ester Linked Macrolides Useful For The Treatment of Microbial Infections | CYP51A1, TLR5, MALT1 | LMNA 2596/4885KMT2A 4129/4885HPGD 1842/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | LMNA 1055/4885KMT2A 3931/4885HPGD 2617/4885 |
| US-20080249033-A1 | Carbamate Linked Macrolides Useful For The Treatment Of Microbial Infections | CYP51A1, CUTA, MALT1 | LMNA 3497/4885KMT2A 2509/4885HPGD 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.